Financial Analysis
Filing-based analysis. Market pricing is not included. Fundamentals from SEC filings; economic data from FRED and the BLS. About our data
Filing evidence summary
Mixed evidenceCoverage 5/5 core metricsLatest reported annual revenue changed -17.8% from the prior reported annual observation.
Backward-looking filed evidence under visible rules - not a rating, forecast or investment advice. Missing data is never scored.
Evidence signals
- Revenue contracted
Latest reported annual revenue changed -17.8% from the prior reported annual observation.
Why this surfaced
Direction threshold: above +2% constructive; below -2% caution; otherwise monitor. This is not labeled one-year growth when filing periods have a gap. Period end 2025-12-31.
- Free cash flow was negative
Latest reported free cash flow was -$6M.
Why this surfaced
Free cash flow = operating cash flow minus capital expenditures; positive is supporting evidence, not a valuation conclusion. Period end 2025-12-31.
- 3 filing risk checks flagged
Flagged areas: Solvency & liquidity, Dilution.
Why this surfaced
The full financial analysis shows each value, threshold, and sector limitation.
- Operating margin improved
Operating margin changed +18.3 percentage points from the prior annual period.
Why this surfaced
Direction threshold: more than +1 percentage point constructive; below -1 point caution. Period end 2025-12-31.
Core trend metrics
Hover a tile for its exact definition; the Statements tab carries per-cell filing citations.
Where to look next
Risk checks
- Solvency & liquidity
- Dilution
Financial movement
- Cash→ flat
- Long-term debt→ flat
- Inventory→ flat
- Receivables→ flat
- Current assets→ flat
Source & freshness
- Source
- SEC EDGAR XBRL
- Fetched
- 2026-09-06
- Latest period end
- 2025-12-31
- Filings
- EDGAR ↗
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Healthcare Operations$39.7M73.1%-24.1% yoy
- Ecommerce Revenue$14.6M26.9%+5.9% yoy
Members sum to the consolidated $54.3M for this period.
- Product$49.7Mshare n/a-10.6% yoy
- Pharmacy Prescription And Other Revenue Net Of Pbm Fees$35.7Mshare n/a-14.8% yoy
- Ecommerce Revenue$14.6Mshare n/a+5.9% yoy
- Service$4.66Mshare n/a-55.8% yoy
- Pharmacy340b Contract$4.01Mshare n/a-61.4% yoy
member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.
- Healthcare Operations$6.66M67.5%-39.0% yoy
- Ecommerce Revenue$3.2M32.5%+6.4% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
Peer percentiles
latest fiscal year ending 2025-12-31 · among 4,122 US-listed filers · 130 in Communication| Metric | Value | vs all filers | vs sector |
|---|---|---|---|
Revenue latest fiscal-year revenue as filed | $54M | 22ndof 3,301 bottom third | 12thof 124 bottom third |
Revenue growth latest fiscal-year revenue vs the prior fiscal year | -17.8% | 7thof 3,135 bottom third | 4thof 119 bottom third |
Gross margin gross profit ÷ revenue | 20.1% | 21stof 1,603 bottom third | 25thof 22 bottom third |
Operating margin operating income ÷ revenue | -16.6% | 28thof 2,819 bottom third | 28thof 117 bottom third |
Free-cash-flow margin (operating cash flow − |capex|) ÷ revenue | -11.4% | 23rdof 2,679 bottom third | 17thof 105 bottom third |
Days sales outstanding receivables ÷ revenue × 365 · lower is ranked higher | 27 days | 76thof 2,398 top third | 65thof 107 middle third |
Balance-sheet accrual ratio change in net operating assets ÷ average net operating assets · lower is ranked higher | -55.5% | 90thof 3,059 top third | 90thof 87 top third |
Each filer's latest fiscal year as stored by the nightly crawl; fiscal year ends differ across the universe. A metric ranks only filers for which it is computable from filed facts. Ties split; a rank reads "better than N% of filers" in the metric's own direction. Descriptive and educational, not a rating.
Earnings quality
latest fiscal year ending 2025-12-31 · accruals and cash conversion as filedPer fiscal year from filed facts: cash conversion = operating cash flow / net income (net income > 0); cash-flow accrual ratio = (net income - operating cash flow) / average total assets; balance-sheet accrual ratio = change in net operating assets / average net operating assets, NOA = (assets - cash) - (liabilities - debt). Descriptive; a missing input yields a missing ratio. High accrual ratios and cash conversion well below one are the measures the accruals literature associates with less persistent earnings; they are screens to read the cash-flow statement with, not conclusions. The per-year series is part of Pro risk analysis.
Point-in-time ledger
first-reported vs latest filing · periods since 2020-01-01 · 17 changed periods| Line item | Period | First reported | Latest filing | Change | Filings |
|---|---|---|---|---|---|
| Depreciation and amortization DepreciationAndAmortization | fiscal year 2024-12-31 | $2.5M 10-K 2025-03-24 | $788K 10-K 2026-03-31 | -68.5% | first · latest |
| Receivables AccountsReceivableNetCurrent | balance at 2025-12-31 | $4.01M 10-K 2026-03-31 | $5.94M 10-Q 2026-08-14 | +48.1% | first · latest · 3 filings carry it |
| Net income NetIncomeLoss | quarter 2025-03-31 | -$1.34M 10-Q 2025-05-15 | -$1.94M 10-Q 2026-05-15 | -44.6% | first · latest |
| Operating income OperatingIncomeLoss | quarter 2025-03-31 | -$1.49M 10-Q 2025-05-15 | -$2.08M 10-Q 2026-05-15 | -40.3% | first · latest |
| Gross profit GrossProfit | quarter 2025-03-31 | $3.46M 10-Q 2025-05-15 | $2.86M 10-Q 2026-05-15 | -17.3% | first · latest |
| Stock-based compensation ShareBasedCompensation | fiscal year 2020-12-31 | $831K 10-K 2021-03-22 | $905K 10-K/A 2022-04-04 | +8.9% | first · latest · 3 filings carry it |
| Gross profit GrossProfit | fiscal year 2024-12-31 | $16.2M 10-K 2025-03-24 | $17M 10-K 2026-03-31 | +4.8% | first · latest |
| Revenue RevenueFromContractWithCustomerIncludingAssessedTax | quarter 2025-03-31 | $14.5M 10-Q 2025-05-15 | $13.9M 10-Q 2026-05-15 | -4.1% | first · latest |
| Operating income OperatingIncomeLoss | fiscal year 2024-12-31 | -$23.6M 10-K 2025-03-24 | -$23M 10-K 2026-03-31 | +2.5% | first · latest |
| Stockholders' equity StockholdersEquity | balance at 2024-12-31 | $26.7M 10-K 2025-03-24 | $27.3M 10-K 2026-03-31 | +2.2% | first · latest · 5 filings carry it |
| Total assets Assets | balance at 2024-12-31 | $36.5M 10-K 2025-03-24 | $37.1M 10-K 2026-03-31 | +1.6% | first · latest · 5 filings carry it |
| Deferred revenue (current) ContractWithCustomerLiabilityCurrent | balance at 2022-12-31 | $36.4K 10-K 2023-03-31 | $36K 10-K 2024-04-11 | -1.1% | first · latest · 5 filings carry it |
| Gross profit GrossProfit | quarter 2024-03-31 | $4.81M 10-Q 2024-05-15 | $4.86M 10-Q 2025-05-15 | +1.1% | first · latest |
| Gross profit GrossProfit | quarter 2024-09-30 | $3.52M 10-Q 2024-11-14 | $3.56M 10-Q 2025-11-13 | +1.1% | first · latest |
| Revenue RevenueFromContractWithCustomerIncludingAssessedTax | fiscal year 2024-12-31 | $65.5M 10-K 2025-03-24 | $66.1M 10-K 2026-03-31 | +0.9% | first · latest |
| Gross profit GrossProfit | quarter 2024-06-30 | $5.81M 10-Q 2024-08-14 | $5.86M 10-Q 2025-08-14 | +0.9% | first · latest |
| Capital expenditure PaymentsToAcquirePropertyPlantAndEquipment | quarter 2023-03-31 | $68.6K 10-Q 2023-05-15 | $69K 10-Q 2024-05-15 | +0.6% | first · latest |
4 share-count periods re-presented for a stock split (1-for-10) are listed apart from restatements and not counted above.
First filing reporting each period vs the latest filing carrying it (10-K and 10-Q only, periods since 2020, the extractor's winning tag per concept); a change under 0.5% is treated as rounding. A change can be a restatement, a reclassification or a re-tagging in a later comparative column; the two filings are linked so the reader can see which. Descriptive, not a verdict.
Notes by disclosure type
Not available for NXPL yet: no footnote text blocks on file for this filer in the ingested DERA files.
Fundamentals from SEC EDGAR. Scores, the DCF, and every model shown are educational analysis, not investment advice or price predictions.